Figure 5.

Dual vector therapeutic effects in the Abca4^−/− mouse model. (A) Representative chromatogram traces for treatment and sham injected eyes. (B) A significant reduction in bisretinoid levels was observed in eyes that received the dual vector treatment compared to paired sham injected eyes (two-way ANOVA with matching values, n = 13, treatment effect p = 0.03, F(1,60) = 4.516). A multiple comparisons test identified a significant difference in A2PE-H₂ levels between treatment and sham injected eyes (*p = 0.01). Bisretinoid levels in WT eyes are presented for reference only and were not included in the analysis. (C) Paired treated and sham injected Abca4^−/− eyes were imaged by scanning laser ophthalmology (SLO). (D) Between 3 and 6 months postinjection, the increase in 790nm autofluorescence was significantly attenuated in eyes that received dual vector (treatment) compared to paired sham-injected eyes (paired t-test, n = 12, *p = 0.04). atRALdi-PE, all-trans-retinal dimer-phosphatidylethanolamine; A2PE-H₂, di-hydro-A2PE; A2PE, N-retinylidene-N-retinylphosphatidylethanolamine; A2E, conjugated N-retinylidene-N-reintylphosphatidylethanolamine; iso-A2E, isomer of A2E; WT, SVEV age-matched controls.